Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Ani Pharmaceuticals (ANIP) EBT Margin (2016 - 2025)

Ani Pharmaceuticals' EBT Margin history spans 15 years, with the latest figure at 12.74% for Q4 2025.

  • For Q4 2025, EBT Margin rose 1996.0% year-over-year to 12.74%; the TTM value through Dec 2025 reached 10.84%, up 1446.0%, while the annual FY2025 figure was 10.84%, 1446.0% up from the prior year.
  • EBT Margin for Q4 2025 was 12.74% at Ani Pharmaceuticals, down from 14.84% in the prior quarter.
  • Across five years, EBT Margin topped out at 18.43% in Q1 2024 and bottomed at 50.65% in Q4 2021.
  • The 5-year median for EBT Margin is 0.49% (2021), against an average of 7.0%.
  • The largest annual shift saw EBT Margin crashed -4652bps in 2021 before it soared 4461bps in 2022.
  • A 5-year view of EBT Margin shows it stood at 50.65% in 2021, then soared by 88bps to 6.03% in 2022, then soared by 112bps to 0.72% in 2023, then plummeted by -1104bps to 7.22% in 2024, then soared by 276bps to 12.74% in 2025.
  • Per Business Quant, the three most recent readings for ANIP's EBT Margin are 12.74% (Q4 2025), 14.84% (Q3 2025), and 4.98% (Q2 2025).